Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index
NCT ID: NCT05946122
Last Updated: 2023-07-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
106 participants
INTERVENTIONAL
2023-05-30
2023-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
NCT00570752
Anti-inflammatory Effect of Atorvastatin in Atherosclerotic Plaques Assessed by FDG-PET Imaging
NCT00920101
Anti-inflammatory Effect of Atorvastatin on Graft Donor Kidney
NCT02355704
Atorvastatin Effects On Arterial Stiffness In Hemodialysis
NCT04472637
Single Dose of Atorvastatin and Circulating Endothelial Microparticles
NCT02023892
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group
placebo drug
tablet resembles atorvastatin
Active ( Ator) group
Atorvastatin 40 Mg Oral Tablet
oral atorvastatin for renal protection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin 40 Mg Oral Tablet
oral atorvastatin for renal protection
placebo drug
tablet resembles atorvastatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pre-admission chronic kidney disease.
* Intra-vascular coagulopathy
* Patients with myopathy.
25 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Minia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mina Maher
lecturer of anesthesia and pain medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mina Maher Raouf
Minya, Minia University, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
343/ 8-2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.